Key Sessions
Sarah Snykers
Transforming Cell Therapy Manufacturing: Legend's Journey from Start Up to Commercial Manufacturing and Beyond
Legend Biotech
Rutger Douma
Establishing a Network to Produce Lentiviral Vectors for Carvykti®
Johnson & Johnson Innovative Medicine
keyboard_arrow_right
Search & Filter keyboard_arrow_right
keyboard_arrow_left Hide
Wednesday 4th November – Day 1 Main Conference - GMT (Greenwich Mean Time, GMTZ)
keyboard_arrow_leftSearch & Filter
search
Streams
Clear
Wednesday 4th November – Day 1 Main Conference - GMT (Greenwich Mean Time, GMTZ)
search
Streams
Clear
Showing 1 of 1 Streams
Gene Therapy Manufacturing & Analytics
11:10 - 11:15
Chairperson’s Opening Remarks: Gene Therapy Manufacturing & Analytics
11:15 - 11:45
Keynote Panel Discussion: Pioneering Gene Therapy Manufacturing: Tackling Bottlenecks to Scale, Boost Potency, Quality and Lower Costs Per Dose
- Gunther Busam - Vice President, Global Manufacturing Technology and Supply, Orchard Therapeutics
11:45 - 12:15
Establishing a Network to Produce Lentiviral Vectors for Carvykti®
- Rutger Douma - MSAT Advanced Therapies Director, Johnson & Johnson Innovative Medicine
12:15 - 12:45
Sponsored Scientific Track Presentation: Implementation of Single Use Technologies for Gene Therapy Manufacturing
Showing 1 of 1 Streams
Gene Therapy Manufacturing & Analytics
14:00 - 14:30
Upstream Innovation to Improve Product Quality and Increase Cell Density in Scalable AAV Production
- Clotilde Ciesla - Upstream Development Engineer, Genethon
14:30 - 15:00
Cell-Free AAV Manufacturing: Redefining Scalability, Quality, and Cost in Gene Therapy
- Jordan Turnbull - Co-Founder, Co-CEO, CSO, Fuse Vectors
15:00 - 15:30
Case Study from VectorY: Revolutionising Large Scale Gene Therapy Production
- Jelmer Willems - Senior Scientist, Group leader, Vector Development, VectorY
Showing 1 of 1 Streams
Gene Therapy Manufacturing & Analytics
16:20 - 16:50
From Bottlenecks to Breakthroughs: Driving Innovation in AAV Downstream Processing for Speed, Scale, and Sustainability
- Parag Kumthekar - Lead Gene Therapy Downstream Process Development, UCB
Get the Latest Event Updates
Sign up to get the latest event updates and information.
Filter
Streams
Clear
